HK1248147A1 - 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 - Google Patents

布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 Download PDF

Info

Publication number
HK1248147A1
HK1248147A1 HK18107889.9A HK18107889A HK1248147A1 HK 1248147 A1 HK1248147 A1 HK 1248147A1 HK 18107889 A HK18107889 A HK 18107889A HK 1248147 A1 HK1248147 A1 HK 1248147A1
Authority
HK
Hong Kong
Prior art keywords
crystalline form
solvate
same
xrpd
compound
Prior art date
Application number
HK18107889.9A
Other languages
English (en)
Chinese (zh)
Inventor
艾瑞克‧戈德曼
M‧S‧史密斯
蒂埃里‧伯诺德
阿尔贝托‧穆诺兹加西亚
克里斯多佛‧彼得‧沃洛
蒂埃裏‧伯諾德
阿爾貝托‧穆諾茲加西亞
克裏斯多佛‧彼得‧沃洛
Original Assignee
药品循环有限责任公司
藥品循環有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 药品循环有限责任公司, 藥品循環有限責任公司 filed Critical 药品循环有限责任公司
Publication of HK1248147A1 publication Critical patent/HK1248147A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18107889.9A 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 HK1248147A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139594P 2015-03-27 2015-03-27
US62/139,594 2015-03-27
PCT/US2016/024305 WO2016160598A1 (en) 2015-03-27 2016-03-25 Solvated forms of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
HK1248147A1 true HK1248147A1 (zh) 2018-10-12

Family

ID=57006292

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18107889.9A HK1248147A1 (zh) 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式
HK18109251.5A HK1249737A1 (zh) 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18109251.5A HK1249737A1 (zh) 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式

Country Status (11)

Country Link
US (4) US20180072738A1 (cg-RX-API-DMAC7.html)
EP (1) EP3273961A4 (cg-RX-API-DMAC7.html)
JP (2) JP2018509457A (cg-RX-API-DMAC7.html)
CN (1) CN107530346A (cg-RX-API-DMAC7.html)
AU (1) AU2016243116A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017020744A2 (cg-RX-API-DMAC7.html)
CA (1) CA2981048A1 (cg-RX-API-DMAC7.html)
HK (2) HK1248147A1 (cg-RX-API-DMAC7.html)
MA (1) MA41827A (cg-RX-API-DMAC7.html)
MX (1) MX2017012430A (cg-RX-API-DMAC7.html)
WO (1) WO2016160598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
WO2017029586A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Crystalline forms of ibrutinib
CZ2016276A3 (cs) * 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
MX2022003340A (es) * 2019-09-18 2022-06-14 Prelude Therapeutics Inc Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
WO2022083733A1 (zh) * 2020-10-23 2022-04-28 上海润石医药科技有限公司 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3303707A1 (de) * 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
WO1993009785A1 (en) 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ES2180548T3 (es) 1992-10-16 2003-02-16 Nippon Shinyaku Co Ltd Metodo de obtencion de matrices de cera.
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
CO5210907A1 (es) * 1999-05-12 2002-10-30 Novartis Ag Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP2157524A3 (en) 2003-09-03 2010-12-08 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for identifying, diagnosing, and predicting survival of lymphomas
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CN103319488A (zh) * 2007-03-28 2013-09-25 环状药物公司 布鲁顿氏酪氨酸激酶抑制剂
US8541391B2 (en) * 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) * 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
CA2875986C (en) * 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
CN106008521A (zh) * 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法

Also Published As

Publication number Publication date
CA2981048A1 (en) 2016-10-06
JP2022033783A (ja) 2022-03-02
CN107530346A (zh) 2018-01-02
JP2018509457A (ja) 2018-04-05
US20200347063A1 (en) 2020-11-05
WO2016160598A1 (en) 2016-10-06
MX2017012430A (es) 2018-07-06
EP3273961A4 (en) 2018-10-31
BR112017020744A2 (pt) 2018-07-17
US20180072738A1 (en) 2018-03-15
EP3273961A1 (en) 2018-01-31
MA41827A (fr) 2018-01-30
US20220106317A1 (en) 2022-04-07
AU2016243116A1 (en) 2017-10-19
HK1249737A1 (zh) 2018-11-09
US20190367519A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
US10294232B2 (en) Crystalline forms of a Bruton's tyrosine kinase inhibitor
US20220242868A1 (en) Co-crystals of a bruton's tyrosine kinase inhibitor
US20220106317A1 (en) Solvated forms of a bruton's tyrosine kinase inhibitor
JP2017523206A (ja) ブルトン型チロシンキナーゼ阻害剤の新規製剤
EA040198B1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА А 1-((R)-3-(4-АМИНО-3-(4-ФЕНОКСИФЕНИЛ)-1H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ)ПИПЕРИДИН-1-ИЛ)ПРОП-2-ЕН-1-ОНА